Dysfunctional serotonergic neuromodulation in mood-regulating circuits underlies many psychiatric diseases, thus understanding regulation of serotonin (5-HT) transmission is of fundamental importance. The 5-HT transporter (SERT) clears 5-HT from extracellular fluid with high-affinity, and is considered a primary controller of the strength and duration of 5-HT signaling. Our studies have revealed that organic cation transporter 3 (OCT3), a low-affinity, but high-capacity transporter of monoamines, plays a critical role in 5-HT clearance as well. Though circuits modulating arousal and emotion are highly complex, processing within the basolateral amygdala (BLA) is considered essential, especially for fear conditioning. The BLA receives dense input from 5-HT neurons in dorsal raphe nucleus (DRN), and BLA principal neurons have numerous fear-regulatory outputs, including dense projections to medial entorhinal cortex (mEC), which serves as a gateway for fear memory information flow into and out of hippocampus. Like SERT, OCT3 is highly expressed in BLA, ideally positioning these transporters to powerfully control extracellular 5-HT and its local neuro-modulatory efficacy. Proposed studies test the hypothesis that 5-HT clearance by OCT3 and SERT in BLA facilitates acquisition and consolidation of fear memory by buffering the rise of 5-HT that normally restrains BLA-mEC neuronal activation by excitatory fear memory-promoting limbic inputs. We posit that fear conditioning stimuli, which lead to fear memory, co-activate limbic and DRN 5-HT inputs to BLA along with activating the hypothalamic-pituitary-adrenal stress axis. OCT3 is potently inhibited by corticosterone, indicating that diminished OCT3 clearance allows 5-HT to rise high enough during fear conditioning to activate 5-HT receptors and effectively buffer limbic excitation of BLA-mEC neurons, decreasing their output and reducing fear memory. We will use state-of-the-art conditional gene deletion strategies to separately and collectively deplete SERT and OCT3 from DRN neurons, combined with optogenetic activation and inhibition of DRN 5-HT neurons projecting directly to BLA. AAV shRNA will be used to knockdown SERT and/or OCT3 on all cell types in BLA. These approaches will be used to determine the relative contributions of SERT and OCT3 to 1) 5-HT clearance in BLA in vivo using high-speed chronoamperometry; 2) 5-HT modulation of BLA-mEC neuronal activity using in vivo single neuron and whole-cell patch clamp recording in brain slices; 3) fear conditioning behavior. Because of their important roles in fear conditioning and 5-HT signaling in BLA, we will interrogate the functional contributions of 5-HT2A and 5-HT1A receptors in this circuit. Serotonergic neurotransmission potently modulates behavior, and its dysregulation is strongly implicated in psychiatric diseases. Proposed, discovery driven, studies will provide unprecedented mechanistic insights into the role 5-HT, and its regulation by SERT and OCT3, play specifically within the DRN-BLA-mEC fear conditioning hub.

Public Health Relevance

Dysfunction of serotonergic neurotransmission underlies many psychiatric diseases, thus understanding regulation of serotonin (5-HT) transmission is of fundamental importance. The serotonin transporter (SERT) and organic cation transporter 3 (OCT3) are integral players in maintaining 5-HT tone, yet how they influence serotonergic neurotransmission in brain circuits crucial for regulating emotion and arousal is unknown. Proposed studies will provide unprecedented mechanistic insights into the role 5-HT, and its regulation by SERT and OCT3, plays in such pathways, and in doing so will inform of novel targets for the treatment of these devastating disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
2R01MH093320-06A1
Application #
9888056
Study Section
Neurotransporters, Receptors, and Calcium Signaling Study Section (NTRC)
Program Officer
Nadler, Laurie S
Project Start
2012-03-01
Project End
2024-08-31
Budget Start
2019-09-12
Budget End
2020-08-31
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Texas Health Science Center
Department
Physiology
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Garbarino, Valentina R; Gilman, T Lee; Daws, Lynette C et al. (2018) Extreme enhancement or depletion of serotonin transporter function and serotonin availability in autism spectrum disorder. Pharmacol Res :
Koek, Wouter; Mitchell, Nathan C; Daws, Lynette C (2018) Biphasic effects of selective serotonin reuptake inhibitors on anxiety: rapid reversal of escitalopram's anxiogenic effects in the novelty-induced hypophagia test in mice? Behav Pharmacol 29:365-369
Gilman, T Lee; George, Christina M; Vitela, Melissa et al. (2018) Constitutive plasma membrane monoamine transporter (PMAT, Slc29a4) deficiency subtly affects anxiety-like and coping behaviours. Eur J Neurosci :
Koek, Wouter; Sandoval, Thomas L; Daws, Lynette C (2018) Effects of the antidepressants desipramine and fluvoxamine on latency to immobility and duration of immobility in the forced swim test in adult male C57BL/6J mice. Behav Pharmacol 29:453-456
Mayer, Felix P; Schmid, Diethart; Owens, W Anthony et al. (2018) An unsuspected role for organic cation transporter 3 in the actions of amphetamine. Neuropsychopharmacology 43:2408-2417
Mitchell, N C; Gilman, T L; Daws, L C et al. (2018) High salt intake enhances swim stress-induced PVN vasopressin cell activation and active stress coping. Psychoneuroendocrinology 93:29-38
Gasser, Paul J; Daws, Lynette C (2017) Extending the family: Roles for uptake2 transporters in regulation of monoaminergic signaling. J Chem Neuroanat 83-84:107-108
Mitchell, Nathan C; Bowman, Melodi A; Gould, Georgianna G et al. (2017) Ontogeny of Norepinephrine Transporter Expression and Antidepressant-Like Response to Desipramine in Wild-Type and Serotonin Transporter Mutant Mice. J Pharmacol Exp Ther 360:84-94
Gasser, Paul J; Daws, Lynette C (2017) Editorial for the special issue: Monoamine transporters in health and disease. J Chem Neuroanat 83-84:1-2
Krause-Heuer, Anwen M; Fraser-Spears, Rheaclare; Dobrowolski, Jeremy C et al. (2017) Evaluation of the antidepressant therapeutic potential of isocyanine and pseudoisocyanine analogues of the organic cation decynium-22. Eur J Med Chem 137:476-487

Showing the most recent 10 out of 22 publications